Home Cart Sign in  
Chemical Structure| 1257-08-5 Chemical Structure| 1257-08-5

Structure of (-)-Epicatechin gallate
CAS No.: 1257-08-5

Chemical Structure| 1257-08-5

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

(-)-Epicatechin gallate, a polyphenol, is a apoptosis inducer of tumor cells that found in green tea.

Synonyms: ECG; (-)-Epicatechin 3-O-gallate; Epicatechin-3-O-gallate.

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of (-)-Epicatechin gallate

CAS No. :1257-08-5
Formula : C22H18O10
M.W : 442.37
SMILES Code : O=C(O[C@H]1[C@@H](C2=CC=C(O)C(O)=C2)OC3=CC(O)=CC(O)=C3C1)C4=CC(O)=C(O)C(O)=C4
Synonyms :
ECG; (-)-Epicatechin 3-O-gallate; Epicatechin-3-O-gallate.
MDL No. :MFCD00075936
InChI Key :LSHVYAFMTMFKBA-TZIWHRDSSA-N
Pubchem ID :107905

Safety of (-)-Epicatechin gallate

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H315-H319-H335
Precautionary Statements:P261-P305+P351+P338

Isoform Comparison

Biological Activity

In Vitro:

Cell Line
Concentration Treated Time Description References
SCC7 cells 100 μM 24 hours ECG suppressed cyclin D1 expression in SCC7 cells in a dose- and time-dependent manner. PMC2430519
SW480 cells 50 μM 24 hours Assessed the effect of ECG on ATF3 expression, results suggested p53 expression may not be involved in catechin-induced ATF3 expression PMC2174270
HCT-116 cells 50 μM 24 hours Induced ATF3 expression, assessed the effect of ECG on ATF3 at the transcriptional level PMC2174270
EMRSA-16 12.5 µg/mL 4 hours To investigate the impact of ECg on phospholipid distribution in the EMRSA-16 cytoplasmic membrane. Results showed that ECg insertion significantly altered cell phenotype, increased cell size and surface roughness, and affected phospholipid distribution. PMC4581164
HCT-116 human colorectal cancer cells 100 μM 48 hours Evaluate the inhibitory effect of ECG on HCT-116 cell proliferation, results showed 100 μM ECG inhibited cell growth by 20.3% PMC3509513
SCC7 cells 50 μM 72 hours ECG significantly inhibited the growth of SCC7 cells via G1 cell cycle arrest and apoptosis induction. PMC2430519

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
Mice TC-1 cell-implanted mice Intra-tumor infusion 64 µM Every 24 h for 5 days Injected TriCurin causes a dramatic suppression of tumors in TC-1 cell-implanted mice, accompanied by repolarization of TAM from M2 to M1-type and intra-tumor recruitment of NK cells and CTL. PMC11028238
Caenorhabditis elegans Wild-type N2 nematodes Smeared on the surface of agar 200, 500, 1000 μM Counted every two days from the first day of adulthood until death Investigated the effect of ECG on lifespan of nematodes, found that ECG could extend lifespan PMC8235257
Sprague-Dawley rats Full thickness incisional model of dermal wound healing Intradermally 0.8 mg/ml Once daily for 7 days ECG significantly improved the quality of scar formation, including the maturity and orientation of collagen fibers. The ECG-treated group showed a significant increase in new blood vessel formation at early time points (days 1 and 3) and upregulation of iNOS and COX-2 activity, while decreasing arginase-I activity and protein levels. These effects may be partly due to an acceleration of the angiogenic response and upregulation of NOS and COX enzymes. PMC1618547

Clinical Trial:

NCT Number Conditions Phases Recruitment Completion Date Locations
NCT00611650 Lung Cancer P... More >>recancerous Condition Tobacco Use Disorder Less << Phase 2 Terminated(Slow recruitment) - Canada, British Columbia ... More >> British Columbia Cancer Agency - Vancouver Cancer Centre Vancouver, British Columbia, Canada, V5Z 4E6 Less <<
NCT00253643 Precancerous Condition ... More >> Prostate Cancer Less << Not Applicable Completed - United States, Oregon ... More >> Kaiser Permanente Center for Health Research Portland, Oregon, United States, 97227 OHSU Knight Cancer Institute Portland, Oregon, United States, 97239-3098 Veterans Affairs Medical Center - Portland Portland, Oregon, United States, 97239 Less <<
NCT00253643 - Completed - -
NCT00596011 Prostatic Hyperplasia Phase 2 Completed - United States, Florida ... More >> University of Florida/Shands-Department of Urology Gainesville, Florida, United States, 32610 University of Florida - Jacksonville Jacksonville, Florida, United States, 32209 Watson Clinic Center for Research, Inc. Lakeland, Florida, United States, 33805 H Lee Moffitt Cancer Center Tampa, Florida, United States, 33612 James A Haley VA Tampa, Florida, United States, 33612 United States, Illinois University of Chicago - Department of Surgery Chicago, Illinois, United States, 60637 United States, Louisiana Overton Brooks VA Medical Center Shreveport, Louisiana, United States, 71101-4295 LSU Health Sciences Center, Feist-Weiller Cancer Center Shreveport, Louisiana, United States, 71130 United States, Minnesota Minneapolis VA Medical Center Minneapolis, Minnesota, United States, 55417 United States, Pennsylvania Jefferson Medical College - Department of Urology Philadelphia, Pennsylvania, United States, 19107 Less <<
NCT00942422 Multiple Myeloma and Plasma Ce... More >>ll Neoplasm Precancerous Condition Less << Phase 2 Terminated(Low accrual and ear... More >>ly termination) Less << - United States, Michigan ... More >> Barbara Ann Karmanos Cancer Institute Detroit, Michigan, United States, 48201 Less <<
NCT00573885 Lung Cancer T... More >>obacco Use Disorder Less << Phase 2 Completed - Canada, British Columbia ... More >> British Columbia Cancer Agency - Vancouver Cancer Centre Vancouver, British Columbia, Canada, V5Z 4E6 Less <<
NCT00596011 - Completed - -
NCT00459407 Adenocarcinoma of the Prostate... More >> Stage I Prostate Cancer Stage II Prostate Cancer Less << Phase 1 Completed - United States, Arizona ... More >> Arizona Cancer Center - Tucson Tucson, Arizona, United States, 85724-5024 Less <<
NCT00799890 Multiple Sclerosis Phase 2 Phase 3 Completed - Germany ... More >> Charité Universitätsmedizin Berlin (NeuroCure Clinical Research Center) Berlin, Germany, 10117 Less <<
NCT03526406 Cognitive Function ... More >> Mood Less << Not Applicable Active, not recruiting September 2018 United Kingdom ... More >> University of Reading Reading, Berkshire, United Kingdom, RG6 6AL Less <<
NCT00942422 - Terminated(Low accrual and ear... More >>ly termination) Less << - -
NCT03194620 Healthy Not Applicable Completed - United States, California ... More >> UC Davis Davis, California, United States, 95616 Less <<

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

2.26mL

0.45mL

0.23mL

11.30mL

2.26mL

1.13mL

22.61mL

4.52mL

2.26mL

References

 

Historical Records

Categories